Cystic fibrosis

Pediatrics in Review

Volumn 35, Issue 5, 2014, Pages 194-205

  Paranjape, Shruti M ^a   Mogayzel Jr , Peter J ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; CORTICOSTEROID; IBUPROFEN; IVACAFTOR; PANCREAS ENZYME;

ARTICLE; CHRONIC RHINOSINUSITIS; CLINICAL FEATURE; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE EXACERBATION; GASTROINTESTINAL HEMORRHAGE; GENETIC ANALYSIS; HEMOPTYSIS; HUMAN; INTESTINE OBSTRUCTION; LIVER DISEASE; LONG TERM CARE; NONHUMAN; NOSE POLYP; NUTRITIONAL STATUS; PANCREAS INSUFFICIENCY; PATHOGENESIS; PNEUMOTHORAX; PROGNOSIS; QUALITY OF LIFE; RESPIRATORY TRACT INFECTION; RESPIRATORY TRACT INFLAMMATION; SURVIVAL; TREATMENT INDICATION; COMPLICATION; GENETICS; LIFE EXPECTANCY;

CYSTIC FIBROSIS; HUMANS; LIFE EXPECTANCY; NUTRITIONAL STATUS; PROGNOSIS;

EID: 84899825299     PISSN: 01919601     EISSN: 15263347     Source Type: Journal    
DOI: 10.1542/pir.35-5-194     Document Type: Article

References (40)

1. Davis PB. Cystic fibrosis since 1938. Am J Respir Crit Care Med. 2006;173(5):475-482
2. Davis PB, Drumm M, Konstan MW. Cystic fibrosis. Am J Respir Crit Care Med. 1996;154(5):1229-1256 (Pubitemid 26391164)
3. Andersen DH. Cystic fibrosis of the pancreas and its relation to celiac disease. Am J Dis Child. 1938;56:344-399
4. Cystic Fibrosis Foundation. 2012 Annual Data Report. Bethesda, MD: Cystic Fibrosis Foundation Patient Registry; 2013
5. Hamosh A, FitzSimmons SC, Macek M Jr, Knowles MR, Rosenstein BJ, Cutting GR. Comparison of the clinical manifestations of cystic fibrosis in black and white patients. J Pediatr. 1998;132(2):255-259 (Pubitemid 28125176)
6. Rohlfs EM, Zhou Z, Heim RA, et al. Cystic fibrosis carrier testing in an ethnically diverse US population. Clin Chem. 2011;57(6):841-848
7. Cystic Fibrosis Mutation Database. http://www.genet.sickkids.on.ca/Home. html2013. Accessed March 17, 2014
8. Boyle MP, De Boeck K. A new era in the treatment of cystic fibrosis: correction of the underlying CFTR defect. Lancet Respir Med. 2013;1(2):158-163
9. Zielenski J. Genotype and phenotype in cystic fibrosis. Respiration. 2000;67(2):117-133 (Pubitemid 30193081)
10. Gibson LE, Cooke RE. A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics. 1959;23(3):545-549
11. Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008;153(2):S4-S14 (Pubitemid 351970581)
12. Boyle MP. Nonclassic cystic fibrosis and CFTR-related diseases. Curr Opin Pulm Med. 2003;9(6):498-503 (Pubitemid 37268214)
13. Paranjape SM, Zeitlin PL. Atypical cystic fibrosis and CFTR-related diseases. Clin Rev Allergy Immunol. 2008;35(3):116-123
14. Leal T, Lebacq J, Lebecque P, Cumps J, Wallemacq P. Modified method to measure nasal potential difference. Clin Chem Lab Med. 2003;41(1):61-67 (Pubitemid 36285387)
15. Wilson DC, Ellis L, Zielenski J, et al. Uncertainty in the diagnosis of cystic fibrosis: possible role of in vivo nasal potential difference measurements. J Pediatr. 1998;132(4):596-599 (Pubitemid 28194576)
16. Standaert TA, Boitano L, Emerson J, et al. Standardized procedure for measurement of nasal potential difference: an outcome measure in multicenter cystic fibrosis clinical trials. Pediatr Pulmonol. 2004;37(5):385-392 (Pubitemid 38620059)
17. Wagener JS, Zemanick ET, Sontag MK. Newborn screening for cystic fibrosis. Curr Opin Pediatr. 2012;24(3):329-335
18. Farrell PM, Rosenstein BJ, White TB, et al Cystic Fibrosis Foundation. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr. 2008;153(2):S4-S14 (Pubitemid 351970581)
19. Borowitz D, Robinson KA, Rosenfeld M, et al Cystic Fibrosis Foundation. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr. 2009;155(6 suppl):S73-S93
20. Borowitz D, Parad RB, Sharp JK, et al Cystic Fibrosis Foundation. Cystic Fibrosis Foundation practice guidelines for the management of infants with cystic fibrosis transmembrane conductance regulator-related metabolic syndrome during the first two years of life and beyond. J Pediatr. 2009;155(6 suppl):S106-S116
21. Flume PA, O'Sullivan BP, Robinson KA, et al Cystic Fibrosis Foundation, Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176(10):957-969 (Pubitemid 350127838)
22. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187(7):680-689
23. Flume PA, Robinson KA, O'Sullivan BP, et al Clinical Practice Guidelines for Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: airway clearance therapies. Respir Care. 2009;54(4):522-537
24. Ramsey BW, Davies J, McElvaney NG, et al; VX08-770-102 Study Group. A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med. 2011;365(18):1663-1672
25. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. N Engl J Med. 2010;363(21):1991- 2003
26. Konstan MW, Davis PB. Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis. Adv Drug Deliv Rev. 2002;54(11):1409-1423 (Pubitemid 35375768)
27. Binder AM, Adjemian J, Olivier KN, Prevots DR. Epidemiology of nontuberculous mycobacterial infections and associated chronic macrolide use among persons with cystic fibrosis. Am J Respir Crit Care Med. 2013;188(7):807-812
28. Borowitz D, Gelfond D, Maguiness K, Heubi JE, Ramsey B. Maximal daily dose of pancreatic enzyme replacement therapy in infants with cystic fibrosis: a reconsideration. J Cyst Fibros. 2013;12(6):784-785
29. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H; Clinical Practice Guidelines on Growth and Nutrition Subcommittee; Ad Hoc Working Group. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. J Am Diet Assoc. 2008;108(5):832-839 (Pubitemid 351602057)
30. Schibli S, Durie PR, Tullis ED. Proper usage of pancreatic enzymes. Curr Opin Pulm Med. 2002;8(6):542-546 (Pubitemid 35204708)
31. Stenbit AE, Flume PA. Pulmonary exacerbations in cystic fibrosis. Curr Opin Pulm Med. 2011;17(6):442-447
32. Flume PA, Mogayzel PJ Jr, Robinson KA, Rosenblatt RL, Quittell L, Marshall BC; Clinical Practice Guidelines for Pulmonary Therapies Committee; Cystic Fibrosis Foundation Pulmonary Therapies Committee. Cystic fibrosis pulmonary guidelines: pulmonary complications: hemoptysis and pneumothorax. Am J Respir Crit Care Med. 2010;182(3):298-306
33. Hurt K, Simmonds NJ. Cystic fibrosis: management of haemoptysis. Paediatr Respir Rev. 2012;13(4):200-205
34. Flume PA. Pneumothorax in cystic fibrosis. Curr Opin Pulm Med. 2011;17(4):220-225
35. Mainz JG, Koitschev A. Pathogenesis and management of nasal polyposis in cystic fibrosis. Curr Allergy Asthma Rep. 2012;12(2):163-174
36. Mainz JG, Koitschev A. Management of chronic rhinosinusitis in CF. J Cyst Fibros. 2009;8(suppl 1):S10-S14
37. Colombo C, Ellemunter H, Houwen R, Munck A, Taylor C, Wilschanski M; ECFS. Guidelines for the diagnosis and management of distal intestinal obstruction syndrome in cystic fibrosis patients. J Cyst Fibros. 2011;10(suppl 2):S24-S28
38. Debray D, Kelly D, Houwen R, Strandvik B, Colombo C. Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease. J Cyst Fibros. 2011;10(suppl 2):S29-S36
39. Kelly A, Moran A. Update on cystic fibrosis-related diabetes. J Cyst Fibros. 2013;12(4):318-331
40. Moran A, Brunzell C, Cohen RC, et al CFRD Guidelines Committee. Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care. 2010;33(12):2697-2708